Expressions of cytochrome P450, UDP-glucuronosyltranferase, and transporter genes in monolayer carcinoma cells change in subcutaneous tumors grown as xenografts in immunodeficient nude mice

Drug Metabolism and Disposition

Volumn 38, Issue 3, 2010, Pages 526-533

  Sugawara, Michiko ^a   Okamoto, Kiyoshi ^a   Kadowaki, Tadashi ^a   Kusano, Kazutomi ^a   Fukamizu, Akiyoshi ^b   Yoshimura, Tsutomu ^a  

^a EISAI CO LTD   (Japan)

^b UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

3 METHYLCHOLANTHRENE; CELL NUCLEUS RECEPTOR; CYTOCHROME P450; CYTOCHROME P450 3A4; DEXAMETHASONE; GLUCURONOSYLTRANSFERASE; PREGNANE X RECEPTOR; RIFAMPICIN; TRANSCRIPTION FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG METABOLISM; FEMALE; GENE CONTROL; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOPRECIPITATION; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKIN TUMOR; TUMOR CELL; TUMOR XENOGRAFT; WESTERN BLOTTING;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CYTOCHROME P-450 ENZYME SYSTEM; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME INDUCTION; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUCURONOSYLTRANSFERASE; HUMANS; MEMBRANE TRANSPORT PROTEINS; MICE; MICE, NUDE; NEOPLASMS, EXPERIMENTAL; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RANDOM ALLOCATION; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS MUSCULUS;

EID: 76749157232     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.109.030668     Document Type: Article

References (42)

1. Aitken AE, Richardson TA, and Morgan ET (2006) Regulation of drug-metabolizing enzymes and transporters in inflammation. Annu Rev Pharmacol Toxicol 46:123-149.
2. Barbier O, Torra IP, Sirvent A, Claudel T, Blanquart C, Duran-Sandoval D, Kuipers F, Kosykh V, Fruchart JC, and Staels B (2003) FXR induces the UGT2B4 enzyme in hepatocytes: a potential mechanism of negative feedback control of FXR activity. Gastroenterology 124:1926-1940.
3. Chang TT and Hughes-Fulford M (2009) Monolayer and spheroid culture of human liver hepatocellular carcinoma cell line cells demonstrate distinct global gene expression patterns and functional phenotypes. Tissue Eng Part A 15:559-567.
4. Cowell JK, Ramani P, Song Y, Evans M, and Morgan G (1997) The use of SCID mice for the growth of retinoblastoma cell lines and for the establishment of xenografts from primary tumours. Eur J Cancer 33:1070-1074.
5. Dannenberg LO and Edenberg HJ (2006) Epigenetics of gene expression in human hepatoma cells: expression profiling the response to inhibition of DNA methylation and histone deacetylation. BMC Genomics 7:181.
6. Durand RE (1990) Slow penetration of anthracyclines into spheroids and tumors: a therapeutic advantage? Cancer Chemother Pharmacol 26:198-204.
7. Erlichman C and Vidgen D (1984) Cytotoxicity of adriamycin in MGH-U1 cells grown as monolayer cultures, spheroids, and xenografts in immune-deprived mice. Cancer Res 44:5369-5375.
8. Finnström N, Thörn M, Lööf L, and Rane A (2001) Independent patterns of cytochrome P450 gene expression in liver and blood in patients with suspected liver disease. Eur J Clin Pharmacol 57:403-409.
9. Guengerich FP and Turvy CG (1991) Comparison of levels of several human microsomal cytochrome P-450 enzymes and epoxide hydrolase in normal and disease states using immunochemical analysis of surgical liver samples. J Pharmacol Exp Ther 256:1189-1194.
10. Hagenbuch B and Gui C (2008) Xenobiotic transporters of the human organic anion transporting polypeptides (OATP) family. Xenobiotica 38:778-801.
11. Harmsen S, Meijerman I, Beijnen JH, and Schellens JH (2007) The role of nuclear receptors in pharmacokinetic drug-drug interactions in oncology. Cancer Treat Rev 33:369-380.
12. Iyer L, Hall D, Das S, Mortell MA, Ramírez J, Kim S, Di Rienzo A, and Ratain MJ (1999) Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism. Clin Pharmacol Ther 65:576-582.
13. Kacevska M, Robertson GR, Clarke SJ, and Liddle C (2008) Inflammation and CYP3A4-mediated drug metabolism in advanced cancer: impact and implications for chemotherapeutic drug dosing. Expert Opin Drug Metab Toxicol 4:137-149.
14. Kojima K, Nagata K, Matsubara T, and Yamazoe Y (2007) Broad but distinct role of pregnane x receptor on the expression of individual cytochrome p450s in human hepatocytes. Drug Metab Pharmacokinet 22:276-286.
15. Kostrubsky VE, Ramachandran V, Venkataramanan R, Dorko K, Esplen JE, Zhang S, Sinclair JF, Wrighton SA, and Strom SC (1999) The use of human hepatocyte cultures to study the induction of cytochrome P-450. Drug Metab Dispos 27:887-894.
16. Kulp SK, Yang YT, Hung CC, Chen KF, Lai JP, Tseng PH, Fowble JW, Ward PJ, and Chen CS (2004) 3-Phosphoinositide-dependent protein kinase-1/Akt signaling represents a major cyclooxygenase-2-independent target for celecoxib in prostate cancer cells. Cancer Res 64:1444-1451.
17. Kyle AH, Huxham LA, Chiam AS, Sim DH, and Minchinton AI (2004) Direct assessment of drug penetration into tissue using a novel application of three-dimensional cell culture. Cancer Res 64:6304-6309.
18. Matsunaga I and Shiro Y (2004) Peroxide-utilizing biocatalysts: structural and functional diversity of heme-containing enzymes. Curr Opin Chem Biol 8:127-132.
19. Michael M and Doherty MM (2007) Drug metabolism by tumours: its nature, relevance and therapeutic implications. Expert Opin Drug Metab Toxicol 3:783-803.
20. Minchinton AI and Tannock IF (2006) Drug penetration in solid tumours. Nat Rev Cancer 6:583-592.
21. Moore LB, Parks DJ, Jones SA, Bledsoe RK, Consler TG, Stimmel JB, Goodwin B, Liddle C, Blanchard SG, Willson TM, et al. (2000) Orphan nuclear receptors constitutive androstane receptor and pregnane X receptor share xenobiotic and steroid ligands. J Biol Chem 275:15122-15127.
22. Nakata K, Tanaka Y, Nakano T, Adachi T, Tanaka H, Kaminuma T, and Ishikawa T (2006) Nuclear receptor-mediated transcriptional regulation in phase I, II, and III xenobiotic metabolizing systems. Drug Metab Pharmacokinet 21:437-457.
23. Nishimura M and Naito S (2005) Tissue-specific mRNA expression profiles of human ATPbinding cassette and solute carrier transporter superfamilies. Drug Metab Pharmacokinet 20:452-477.
24. Nishimura M, Yoshitsugu H, Naito S, and Hiraoka I (2002) Evaluation of gene induction of drug-metabolizing enzymes and transporters in primary culture of human hepatocytes using high-sensitivity real-time reverse transcription PCR. Yakugaku Zasshi 122:339-361.
25. Nozawa T, Minami H, Sugiura S, Tsuji A, and Tamai I (2005) Role of organic anion transporter OATP1B1 (OATP-C) in hepatic uptake of irinotecan and its active metabolite, 7-ethyl-10-hydroxycamptothecin: in vitro evidence and effect of single nucleotide polymorphisms. Drug Metab Dispos 33:434-439.
26. Okabe M, Szakács G, Reimers MA, Suzuki T, Hall MD, Abe T, Weinstein JN, and Gottesman MM (2008) Profiling SLCO and SLC22 genes in the NCI-60 cancer cell lines to identify drug uptake transporters. Mol Cancer Ther 7:3081-3091.
27. Olsavsky KM, Page JL, Johnson MC, Zarbl H, Strom SC, and Omiecinski CJ (2007) Gene expression profiling and differentiation assessment in primary human hepatocyte cultures, established hepatoma cell lines, and human liver tissues. Toxicol Appl Pharmacol 222:42-56.
28. Panduro A, Shalaby F, and Shafritz DA (1987) Changing patterns of transcriptional and post-transcriptional control of liver-specific gene expression during rat development. Genes Dev 1:1172-1182.
29. Patterson LH and Murray GI (2002) Tumour cytochrome P450 and drug activation. Curr Pharm Des 8:1335-1347.
30. Pawlak G and Helfman DM (2001) Cytoskeletal changes in cell transformation and tumorigenesis. Curr Opin Genet Dev 11:41-47.
31. Robertson GR, Liddle C, and Clarke SJ (2008) Inflammation and altered drug clearance in cancer: transcriptional repression of a human CYP3A4 transgene in tumor-bearing mice. Clin Pharmacol Ther 83:894-897.
32. Shimada T, Yamazaki H, Mimura M, Inui Y, and Guengerich FP (1994) Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270:414-423.
33. Smith G, Harrison DJ, East N, Rae F, Wolf H, and Wolf CR (1993) Regulation of cytochrome P450 gene expression in human colon and breast tumour xenografts. Br J Cancer 68:57-63.
34. Spear BT (1999) α-Fetoprotein gene regulation: lessons from transgenic mice. Semin Cancer Biol 9:109-116.
35. Sugawara M, Okamoto K, Kadowaki T, Kusano K, Fukamizu A, and Yoshimura T (2009) Inoculation of human tumor cells alters the basal expression but not the inducibility of cytochrome P450 enzymes in tumor-bearing mouse liver. Drug Metab Dispos 37:2244-2254.
36. Tilghman SM and Belayew A (1982) Transcriptional control of the murine albumin/α-fetoprotein locus during development. Proc Natl Acad Sci U S A 79:5254-5257.
37. Wortham M, Czerwinski M, He L, Parkinson A, and Wan YJ (2007) Expression of constitutive androstane receptor, hepatic nuclear factor 4α, and P450 oxidoreductase genes determines interindividual variability in basal expression and activity of a broad scope of xenobiotic metabolism genes in the human liver. Drug Metab Dispos 35:1700-1710.
38. Xu C, Li CY, and Kong AN (2005) Induction of phase I, II and III drug metabolism/transport by xenobiotics. Arch Pharmacol Res 28:249-268.
39. Yu LJ, Matias J, Scudiero DA, Hite KM, Monks A, Sausville EA, and Waxman DJ (2001) P450 enzyme expression patterns in the NCI human tumor cell line panel. Drug Metab Dispos 29:304-312.
40. Zhou J, Zhang J, and Xie W (2005) Xenobiotic nuclear receptor-mediated regulation of UDP-glucuronosyl-transferases. Curr Drug Metab 6:289-298.
41. Zietarska M, Maugard CM, Filali-Mouhim A, Alam-Fahmy M, Tonin PN, Provencher DM, and Mes-Masson AM (2007) Molecular description of a 3D in vitro model for the study of epithelial ovarian cancer (EOC). Mol Carcinog 46:872-885.
42. Zuber R, Anzenbacherová E, and Anzenbacher P (2002) Cytochromes P450 and experimental models of drug metabolism. J Cell Mol Med 6:189-198.